HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.08.054v1 49/3/290    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JACC Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (23) Citing Articles via Google Scholar Google Scholar Articles by Hanefeld, M. Articles by Forst, T. Search for Related Content PubMed Articles by Hanefeld, M. Articles by Forst, T.

CLINICAL RESEARCH: CLINICAL TRIAL

Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein

The PIOSTAT Study

Markolf Hanefeld, MD, PhD^_*,_*, Nikolaus Marx, MD, Andreas Pfützner, MD, PhD, Werner Baurecht, MSc, Georg Lübben, MD^||, Efstrathios Karagiannis, MD^||, Ulf Stier, MD^_* and Thomas Forst, MD

^_* GWT, Center for Clinical Studies, Dresden, Germany
University Ulm, Medical Department II, Ulm, Germany
Institute for Clinical Research and Development, Mainz, Germany
Acromion, Frechen, Germany
^|| Takeda Pharma, Aachen, Germany.

Manuscript received April 11, 2006; revised manuscript received August 24, 2006, accepted August 28, 2006.

^_* Reprint requests and correspondence: Dr. Markolf Hanefeld, Forschungshereich Endokrinologie and Stoffwechsel, Zentrum für Klinische Studien, GWT-TUD mbH, Fiedlerstrasse 34, 01307 Dresden, Germany. (Email: hanefeld{at}gwtonline-zks.de).

OBJECTIVES: The purpose of this study was to test the safety and efficacy of pioglitazone and simvastatin in combination versus each drug individually in non-diabetic subjects with cardiovascular disease (CVD) and elevated high-sensitivity C-reactive protein (hs-CRP) levels.

BACKGROUND: Low-grade inflammation is a pathogenic factor for atherosclerosis. High-sensitivity CRP, matrix metalloproteinase (MMP)-9, and plasminogen activator inhibitor (PAI)-1 are markers of inflammation. Statins and peroxisome proliferator-activated receptor (PPAR)- agonists lower inflammatory markers and reduce CVD in type 2 diabetes.

METHODS: In a 12-week, prospective, double-blind trial, 125 subjects were randomized to simvastatin or pioglitazone plus placebo or a simvastatin/pioglitazone combination. We tested changes in hs-CRP by analysis of covariance. A subgroup analysis was performed in patients with and without the metabolic syndrome (MetS). The correlation between changes in hs-CRP and homeostasis model assessment (HOMA; a measure of insulin resistance) was calculated with the Spearman’s rank test.

RESULTS: At baseline, there were no significant between-group differences. At 12 weeks, pioglitazone and simvastatin monotherapies significantly reduced hs-CRP (3.64 ± 2.42 mg/l to 2.48 ± 1.77 mg/l and 3.26 ± 2.02 mg/l to 2.81 ± 2.11 mg/l) and the combination regimen had an additive effect (from 3.49 ± 1.97 mg/l to 2.06 ± 1.42 mg/l, p < 0.001). For subgroups, the difference between monotherapy and combination therapy was only significant for simvastatin versus simvastatin plus pioglitazone in patients without MetS. Homeostasis model assessment decreased in those receiving pioglitazone, and the correlation between changes in HOMA and hs-CRP was significant (r = 0.43; p < 0.05). The PAI-1 decreased significantly in the pioglitazone groups only, and MMP-9 was also significantly lowered in the pioglitazone groups. No treatment-related serious adverse events occurred in any group.

CONCLUSIONS: Pioglitazone, probably by reducing insulin resistance, has additive anti-inflammatory effects to simvastatin in non-diabetic subjects with CVD and high hs-CRP.

Abbreviations and Acronyms   CVD = cardiovascular disease   HOMA = homeostasis model assessment   hs-CRP = high-sensitivity C-reactive protein   MCP = macrophage chemoattractant protein   MetS = metabolic syndrome   MMPs = matrix metalloproteinases   PAI = plasminogen activator inhibitor   PPAR = peroxisome proliferator-activated receptor   TZD = thiazolidinediones

Related articles in JACC:

Inside This Issue of JACC

JACC 2007 49: A25-A26. [Full Text]  

This article has been cited by other articles:

				D. K. McGuire and S. E. Inzucchi New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications Circulation, January 22, 2008; 117(3): 440 - 449. [Full Text] [PDF]

				H. I Katcher, R. S Legro, A. R Kunselman, P. J Gillies, L. M Demers, D. M Bagshaw, and P. M Kris-Etherton The effects of a whole grain enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome Am. J. Clinical Nutrition, January 1, 2008; 87(1): 79 - 90. [Abstract] [Full Text] [PDF]

				K. A. McAuley, J. I. Mann, J. G. Chase, T. F. Lotz, and G. M. Shaw Point: HOMA Satisfactory for the Time Being: HOMA: The best bet for the simple determination of insulin sensitivity, until something better comes along Diabetes Care, September 1, 2007; 30(9): 2411 - 2413. [Full Text] [PDF]

				C. V. Leier and G. J. Haas Diabetes and Heart Failure: The Role of Thiazolidinediones in Managing These Partners in Crime J. Am. Coll. Cardiol., July 3, 2007; 50(1): 37 - 39. [Full Text] [PDF]

				E. Erdmann, J. A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I. K. Moules, A. M. Skene, and on behalf of the PROactive Investigators The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction: Results From the PROactive (PROactive 05) Study J. Am. Coll. Cardiol., May 1, 2007; 49(17): 1772 - 1780. [Abstract] [Full Text] [PDF]